Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059459008> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2059459008 startingPage "1907" @default.
- W2059459008 abstract "Background: Nintedanib, an intracellular inhibitor of tyrosine kinases, is in development for the treatment of idiopathic pulmonary fibrosis (IPF). The INPULSIS™ trials were two replicate randomized, double-blind, placebo-controlled, 52-week Phase III trials that assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with IPF. The primary endpoint was the annual rate of decline in forced vital capacity (FVC), which was significantly reduced in the nintedanib group compared with placebo in both trials. Aim: To assess the impact of baseline FVC on the effect of nintedanib on rate of decline in FVC. Methods: A pre-specified subgroup analysis of patients with baseline FVC >70% versus ≤70% of predicted value was undertaken using pooled data from both trials. Results: 700 patients (nintedanib 431, placebo 269) had baseline FVC >70% predicted and 361 patients (nintedanib 207, placebo 154) had baseline FVC ≤70% predicted. For patients with a baseline FVC >70% predicted, mean age was 67.4 years, 76.9% were male, 55.7% were White and mean carbon monoxide diffusion capacity (DL CO ) was 4.0 mmol/min/kPa. For patients with a baseline FVC ≤70% predicted, mean age was 65.5 years, 83.9% were male, 60.4% were White and mean DL CO was 3.6 mmol/min/kPa. There was no significant treatment by subgroup interaction: the difference in adjusted annual rate of decline in FVC between the nintedanib and placebo groups was comparable in both subgroups. Conclusion: A subgroup analysis of pooled data from the INPULSIS™ trials showed that nintedanib 150 mg twice daily slowed the decline in lung function in patients with IPF, independent of severity of lung function impairment at baseline." @default.
- W2059459008 created "2016-06-24" @default.
- W2059459008 creator A5002422862 @default.
- W2059459008 creator A5019441565 @default.
- W2059459008 creator A5029218290 @default.
- W2059459008 creator A5065453273 @default.
- W2059459008 creator A5071431376 @default.
- W2059459008 creator A5090203143 @default.
- W2059459008 creator A5091576695 @default.
- W2059459008 date "2014-09-01" @default.
- W2059459008 modified "2023-09-23" @default.
- W2059459008 title "Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials" @default.
- W2059459008 hasPublicationYear "2014" @default.
- W2059459008 type Work @default.
- W2059459008 sameAs 2059459008 @default.
- W2059459008 citedByCount "0" @default.
- W2059459008 crossrefType "journal-article" @default.
- W2059459008 hasAuthorship W2059459008A5002422862 @default.
- W2059459008 hasAuthorship W2059459008A5019441565 @default.
- W2059459008 hasAuthorship W2059459008A5029218290 @default.
- W2059459008 hasAuthorship W2059459008A5065453273 @default.
- W2059459008 hasAuthorship W2059459008A5071431376 @default.
- W2059459008 hasAuthorship W2059459008A5090203143 @default.
- W2059459008 hasAuthorship W2059459008A5091576695 @default.
- W2059459008 hasConcept C126322002 @default.
- W2059459008 hasConcept C142724271 @default.
- W2059459008 hasConcept C165637977 @default.
- W2059459008 hasConcept C187960798 @default.
- W2059459008 hasConcept C203092338 @default.
- W2059459008 hasConcept C204787440 @default.
- W2059459008 hasConcept C27081682 @default.
- W2059459008 hasConcept C2777714996 @default.
- W2059459008 hasConcept C2778341716 @default.
- W2059459008 hasConcept C2780171596 @default.
- W2059459008 hasConcept C3018587741 @default.
- W2059459008 hasConcept C44249647 @default.
- W2059459008 hasConcept C535046627 @default.
- W2059459008 hasConcept C55520419 @default.
- W2059459008 hasConcept C71924100 @default.
- W2059459008 hasConceptScore W2059459008C126322002 @default.
- W2059459008 hasConceptScore W2059459008C142724271 @default.
- W2059459008 hasConceptScore W2059459008C165637977 @default.
- W2059459008 hasConceptScore W2059459008C187960798 @default.
- W2059459008 hasConceptScore W2059459008C203092338 @default.
- W2059459008 hasConceptScore W2059459008C204787440 @default.
- W2059459008 hasConceptScore W2059459008C27081682 @default.
- W2059459008 hasConceptScore W2059459008C2777714996 @default.
- W2059459008 hasConceptScore W2059459008C2778341716 @default.
- W2059459008 hasConceptScore W2059459008C2780171596 @default.
- W2059459008 hasConceptScore W2059459008C3018587741 @default.
- W2059459008 hasConceptScore W2059459008C44249647 @default.
- W2059459008 hasConceptScore W2059459008C535046627 @default.
- W2059459008 hasConceptScore W2059459008C55520419 @default.
- W2059459008 hasConceptScore W2059459008C71924100 @default.
- W2059459008 hasOpenAccess W2059459008 @default.
- W2059459008 hasRelatedWork W2038320582 @default.
- W2059459008 hasRelatedWork W2056570112 @default.
- W2059459008 hasRelatedWork W2098545954 @default.
- W2059459008 hasRelatedWork W2341412218 @default.
- W2059459008 hasRelatedWork W2487795285 @default.
- W2059459008 hasRelatedWork W2524005801 @default.
- W2059459008 hasRelatedWork W2555363460 @default.
- W2059459008 hasRelatedWork W2556832538 @default.
- W2059459008 hasRelatedWork W2557106527 @default.
- W2059459008 hasRelatedWork W2561981946 @default.
- W2059459008 hasRelatedWork W2569832671 @default.
- W2059459008 hasRelatedWork W2777232717 @default.
- W2059459008 hasRelatedWork W2811389906 @default.
- W2059459008 hasRelatedWork W2901235303 @default.
- W2059459008 hasRelatedWork W2991162217 @default.
- W2059459008 hasRelatedWork W3082109398 @default.
- W2059459008 hasRelatedWork W3096317577 @default.
- W2059459008 hasRelatedWork W3097038268 @default.
- W2059459008 hasRelatedWork W3107410078 @default.
- W2059459008 hasRelatedWork W2529939697 @default.
- W2059459008 hasVolume "44" @default.
- W2059459008 isParatext "false" @default.
- W2059459008 isRetracted "false" @default.
- W2059459008 magId "2059459008" @default.
- W2059459008 workType "article" @default.